Free tool
FAERS Monitor: Sorilux
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022563 or its brand name (Sorilux, Calcipotriene). Reports on generic versions are filed under their own applications.
Reports
3,507
Serious
1,417
40% of reports
Hospitalization
491
Death reported
69
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective843
- psoriasis736
- diarrhoea216
- arthralgia205
- rash197
- nausea190
- pain189
- pruritus184
- off label use179
- headache174
- product use in unapproved indication159
- fatigue150
- therapeutic product effect incomplete146
- psoriatic arthropathy139
- product dose omission issue127
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 6 |
| 2005 | 10 |
| 2006 | 12 |
| 2007 | 16 |
| 2008 | 31 |
| 2009 | 21 |
| 2010 | 24 |
| 2011 | 6 |
| 2012 | 29 |
| 2013 | 53 |
| 2014 | 55 |
| 2015 | 136 |
| 2016 | 149 |
| 2017 | 173 |
| 2018 | 185 |
| 2019 | 247 |
| 2020 | 230 |
| 2021 | 230 |
| 2022 | 223 |
| 2023 | 947 |
| 2024 | 256 |
| 2025 | 265 |
| 2026 | 203 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,652 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| psoriasisSignal | 736 | 34.0 | 31.9 | 23,541 |
| psoriatic arthropathySignal | 139 | 20.6 | 17.5 | 2,570 |
| therapeutic product effect incompleteSignal | 146 | 12.3 | 10.5 | 1,511 |
| product use in unapproved indicationSignal | 159 | 3.8 | 3.3 | 336 |
| drug ineffectiveSignal | 843 | 3.8 | 3.6 | 1,883 |
| arthralgiaSignal | 205 | 3.0 | 2.6 | 269 |
| pruritusSignal | 184 | 2.9 | 2.5 | 227 |
| rashSignal | 197 | 2.7 | 2.4 | 215 |
| product dose omission issueSignal | 127 | 2.6 | 2.2 | 124 |
| diarrhoeaSignal | 216 | 2.0 | 1.8 | 112 |
| pain | 189 | 1.8 | 1.6 | 75 |
| headache | 174 | 1.7 | 1.4 | 47 |
| nausea | 190 | 1.4 | 1.3 | 26 |
| off label use | 179 | 1.2 | 1.1 | 8 |
| fatigue | 150 | 1.2 | 1.0 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.